The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


News Update

Biopharma Receives PDUFA Goal Date for Nonopioid Pain Drug

News Update
  ()
The FDA deemed the firm's submission for analgesic approval complete. read more >

Top Pick Status Given to Small-Cap with Pain Drug Candidate

Research Report
  ()
The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report. read more >

Seattle Genetics Shares Head Higher After Positive Earnings and ADCETRIS Sales Expansion

  ()
Seattle Genetics announced a 28.3% increase in net sales for its second quarter 2019 powered by ADCETRIS sales along with a promising pipeline. read more >

Biopharma's Brain Cancer Therapeutic Compelling, Its Stock Undervalued

Research Report
  ()
A description of the asset and its potential are provided in a Dawson James report. read more >

Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead

  ()
Galapagos announced that Gilead Sciences has agreed to pay $3.95 billion for a 10-year partnership and licensing deal and will invest an additional $1.1 billion in newly issued shares of the company. read more >

Illumina Shares Fall Sharply on Lower Revenue Guidance

  ()
Illumina Inc. shares traded down more than 15% as the company reported lower preliminary Q2/19 revenues and updated its annual revenue guidance. read more >

CVS Declares Quarterly Dividend and Gets a Boost from Relaxed Rebate Policy

  ()
CVS Healthcare announced a $0.50/share quarterly dividend and got an added boost as news spreads regarding easing of federal restrictions on pharmacy rebate plans. read more >

Biopharma Starts 'Key Catalyst Period,' H2/19, with Clinical Trial in New Indication

Research Report
  ()
A study description and expected data readouts this year are provided in a ROTH Capital Partners report. read more >

Coverage Initiated on U.S. Biotech with a 'Potential Best-of-Breed Oncolytic Virus'

Research Report
  ()
The investment thesis on this immunotherapies developer is made in an H.C. Wainwright & Co. report. read more >

Sangamo and Pfizer Report Positive Results for Hemophilia A Study

  ()
Sangamo Therapeutics and partner Pfizer reported positive results for phase 1/2 Alta study for hemophilia A at the International Society on Thrombosis and Hemostasis Congress in Melbourne, Australia. read more >

Coverage Initiated on Biopharma With 'Low Risk/High Margin Assets'

Research Report
  ()
The case is made in a ROTH Capital Partners report for investing in this U.S.-based pharma having multiple shots on goal. read more >

Amarin Shares Up Sharply on Increased Revenues and Vascepa's Progress

  ()
Amarin shares are spiking up today by more than 12% on greater than five times 50-day average volume after the company updated its annual revenue forecast and plans for Vascepa. read more >

Bioasis Engages With the FDA: Here's What It Means

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research examines the implications of correspondence with the regulatory agency as the company advances its lead candidate addressing brain cancer. read more >

Biopharma Buys 'Insurance Policy Ahead of First Commercial Launch'

Research Report
  ()
The terms of the financial transaction and the potential reasons for it are discussed in a BTIG report. read more >

Coverage Initiated on Developer of Neurodegenerative Disease Therapeutics

Research Report
  ()
An H.C. Wainwright & Co. report presented the investment bank's reasons for its bullish view on this California-based biotech. read more >
News Update

Biotech's Data Well Received at Neurodegenerative Diseases Symposium

News Update
  ()
The company shared findings from its lead clinical program, in Alzheimer's disease. read more >
News Update

Biopharma Responds to FDA Inquiry Concerning Non-Opioid Pain Reliever

News Update
  ()
The firm believes adequate therapeutic safety and efficacy data exist to support regulatory approval. read more >

Dova Pharmaceuticals Shares Increase 35% Overnight with FDA Approval

  ()
The pharmaceutical stock enjoyed a large boost, thanks largely to FDA approval of its supplemental new drug application for DOPTELET for treatment of chronic immune thrombocytopenia. read more >

Coverage Initiated on 'Solid Platform Company' with Sanofi Partnership

Research Report
  ()
The reasons why this biopharma makes a compelling investment are outlined in a ROTH Capital Partners report. read more >

Strategic Partnership Highlights Global Ambitions for NASH Therapy

Research Report
  ()
The deal terms and the partner's attractive attributes are discussed in an H.C. Wainwright & Co. report. read more >
News Update

Biotech in Neuro Diseases Adds Parkinson's Expert to Scientific Advisory Board

News Update
  ()
The expert brings to the board a deep knowledge of neurodegeneration. read more >

Biotech Reports 'Eye-Catching, Topline Results' from RSV Vaccine Study

Research Report
  ()
The data and how the asset stacks up to others were covered in a ROTH Capital Partners report. read more >

Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study

Research Report
  ()
The highlights of the results were presented in an H.C. Wainwright & Co. report. read more >
News Update

Biopharma Advances Dose Escalation Trial in Alcoholic Hepatitis

News Update
  ()
The company received approval to proceed with the next and final dose level. read more >

Interim Results Put Biopharma with Tenbagger Potential 'Back on the Map'

Research Report
  ()
A key upcoming catalyst and the impact of recent positive trial results are addressed in a ROTH Capital Partners report. read more >
Showing Results: 1 to 25 of 89 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"We are initiating coverage on AZZ with a Buy rating."
– Colin Healey, Haywood Securities
"ABN looks priced right for a move back into our Buy column."
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"Operations at PVG's Brucejack mine site showed well."
– Andrew Kaip, BMO Capital Markets